Search

Your search keyword '"Fusaro Enrico"' showing total 343 results
Start Over Author "Fusaro Enrico"
343 results on '"Fusaro Enrico"'

1. Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients

Author

Simone Parisi, Becciolini Andrea, Ditto Maria Chiara, Alberto Lo Gullo, Larosa Maddalena, Scolieri Palma, Addimanda Olga, Reta Massimo, Marino Paroli, Caccavale Rosalba, Visalli Elisa, Foti Rosario, Amato Giorgio, De Lucia Francesco, Dal Bosco Ylenia, Foti Roberta, Farina Antonella, Girelli Francesco, Bernardi Simone, Camellino Dario, Bianchi Gerolamo, Colina Matteo, Andracco Romina, Mansueto Natalia, Ferrero Giulio, Del Medico Patrizia, Molica Colella Aldo, Franchina Veronica, Molica Colella Francesco, Lumetti Federica, Sandri Gilda, Salvarani Carlo, Priora Marta, Ianniello Aurora, Nucera Valeria, Santilli Daniele, Lucchini Gianluca, Giuditta Adorni, Di Donato Eleonora, Bravi Elena, Platè Ilaria, Arrigoni Eugenio, Bezzi Alessandra, Focherini Maria Cristina, Mascella Fabio, Bruzzese Vincenzo, Ravagnani Viviana, Fiorenza Alessia, Rovera Guido, Vitetta Rosetta, Marchetta Antonio, Volpe Alessandro, Ometto Francesca, Ariani Alarico, and Fusaro Enrico

Subjects
JAK inhibitors, tsDMARD, bDMARD, Rheumatoid arthritis, Survival rate, Baricitinib, Therapeutics. Pharmacology, RM1-950
Abstract

Objectives: The persistence in therapy of rheumatoid arthritis drugs and particularly bDMARD is a limiting factor for their long-term use. The randomized controlled trials (RCTs) may not reflect real-world contexts due to strict inclusion and exclusion criteria. Baricitinib, which targets both JAK1 and JAK2, has been used in Italy for several years. The aim of this multi-center study is to assess the real world persistence on therapy of baricitinib in RA patients and to identify predictive factors of baricitinib's survival rate. Methods: This is a retrospective, multicentric, Italian, longitudinal study. All patients were enrolled according to the following criteria: a) age ≥ 18 years old; b) diagnosed with RA according 2010 ACR/EULAR classification criteria; c) treated with baricitinib. In order to describe baricitinib clinical efficacy, the survival rate was evaluated by The Kaplan–Meier curve. Then, predictive factors of drug retention rate were assessed by performing the Cox analysis, identifying which risk factors influenced treatment persistence. Results: Overall, we included 478 patients treated with baricitinib. Among them, 380 (79.5%) were females. Baricitinib's survival rate was 94.6% at 6 months, 87.9% at 12 months, 81.7% at 24 months and 53.4% at 48 months. The Cox analysis regression showed that a higher bDMARDs/tsDMARD line of therapy seems to be a negative prognostic factor for the drug retention rate (HR 1.26 CI 95% 1.07–1.49, p = 0.006. Conclusion: Real-life study confirms baricitinib effectiveness up to 4 years, but previous treatment with bDMARDs was a negative prognostic factor for its survival rate.

Published
2024
Full Text
View/download PDF

2. The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A Post Hoc Gender Analysis

Author

Delia Colombo, Micol Frassi, Giuseppa Pagano Mariano, Enrico Fusaro, Claudia Lomater, Patrizia Del Medico, Florenzo Iannone, Rosario Foti, Massimiliano Limonta, Antonio Marchesoni, Bernd Raffeiner, Ombretta Viapiana, Marco Di Carlo, Rosa Daniela Grembiale, Giuliana Guggino, Paola Faggioli, Enrico Tirri, Roberto Perricone, Pier Carlo Sarzi Puttini, Salvatore De Vita, Fabrizio Conti, Sara Rizzoli, Barbara Roncari, Martina Fiocchi, Roberto Orsenigo, Emanuela Zagni, Collaboration group, Frassi Micol, Caminiti Maurizio, Fusaro Enrico, Lomater Claudia, Del Medico Patrizia, Iannone Fiorenzo, Foti Rosario, Limonta Massimiliano, Marchesoni Antonio, Raffeiner Bernd, Viapiana Ombretta, Grassi Walter, Grembiale Rosa Daniela, Guggino Giuliana, Mazzone Antonino, Tirri Enrico, Perricone Roberto, Sarzi Puttini Pier Carlo, De Vita Salvatore, and Conti Fabrizio

Subjects
biologics, effectiveness, gender differences, psoriatic arthritis, real-world evidence, observational study, Gynecology and obstetrics, RG1-991, Public aspects of medicine, RA1-1270
Abstract

Background: Phenotypic features and outcome differences between sexes have been reported in psoriatic arthritis (PsA). However, little is known about sex differences in effectiveness of biologics in clinical practice. Methods: Post hoc gender analysis of the CHRONOS, a multicenter, noninterventional, retroprospective Italian real-world study assessing 6-month and 1-year effectiveness of biologics for PsA. Results: Eligible patients were 399, 43.1% men. Sociodemographic characteristics, type of arthritis, baseline Disease Activity Score 28 joints (DAS28), and duration of biologic treatment were rather homogeneous. More men were overweight/obese and naive to biologics. The most frequently used biologics were TNF-inhibitors and secukinumab in both sexes. DAS28 responders were 72.7% (women) and 70.5% (men) at 6 months, and 68.0% in both sexes at 1 year. American College of Rheumatology (ACR) response showed a trend for men versus women to achieve more frequently ACR50 (32.6% vs. 26.5% at 6 months; 34.9% vs. 20.0% at 1 year) and ACR70 (22.3% vs. 12.4% at 6 months and 25.0% vs. 13.0% at 1 year). Global satisfaction with treatment at enrollment and after 6 months was slightly higher among men [mean (standard deviation) Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) score: 68.6 (18.6) and 69.9 (18.2), respectively] than women [65.3 (18.2), 66.2 (18.5)]. Conclusions: Overall response to biologics for PsA was rather favorable. With similar baseline disease severity, men appear to have a somewhat earlier and better response with higher treatment satisfaction.

Published
2022
Full Text
View/download PDF

3. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry ‘SPRING’ of the Italian Society for Rheumatology

Author

Carlo Alberto Scirè, Andrea Doria, Marcello Govoni, Gerolamo Bianchi, Marco Matucci-Cerinic, Florenzo Iannone, Ennio Lubrano, Corrado Campochiaro, Veronica Codullo, Alessandra Della Rossa, Gemma Lepri, Elisabetta Zanatta, Beretta Lorenzo, Doria Andrea, Lepri Gemma, Lorenzo Beretta, Greta Carrara, Alarico Ariani, Simone Parisi, Marta Saracco, Francesco Girelli, Maria De Santis, Federica Lumetti, Dilia Giuggioli, Enrico Fusaro, Simone Barsotti, Ilaria Cavazzana, Federica Furini, Carlo Salvarani, Serena Guiducci, Franco Cozzi, Valeria Riccieri, Francesca Ingegnoli, Edoardo Rosato, Antonietta Gigante, Rosario Foti, Elisa Visalli, Fabio Cacciapaglia, Lorenzo Dagna, Franco Franceschini, Silvia Bellando-Randone, Giovanna Cuomo, Gianluigi Bajocchi, Alessandro Giollo, Giacomo De Luca, Giuseppina Abignano, Carlo Sciré, Anna Zanetti, Giovanni Zanframundo, Edoardo Cipolletta, Silvia Laura Bosello, Clodoveo Ferri, Amelia Spinella, Giuseppa Pagano Mariano, Maurizio Caminiti, Giuseppe Murdaca, Salvatore D'Angelo, Gianpiero Landolfi, Nicoletta Romeo, Gian Domenico Sebastiani, Erika Pigatto, Rossella De Angelis, Davide Rozza, Maria-Grazia Lazzaroni, Anna Maria Iuliano, Giovanni Ciano, Gianluca Bagnato, Ilenia De Andres, Cecilia Agnes, Luca Magnani, Claudio Di Vico, Greta Pellagrino, Elena Generali, Gianna Mennillo, Licia Vultaggio, Clara Lisa Peroni, Abignano Giuseppina, Agnes Cecilia, Amato Giorgio, Ariani Alarico, Bagnato Gianluca, Bajoicchi Gianluigi, Barsotti Simone, Bellando-Randone Silvia, Benenati Alessia, Bianchi Gerolamo, Bosello Silvia, Cacciapaglia Fabio, Calabrese Francesca, Caminiti Maurizio, Campochiaro Corrado, Carignola Renato, Ciano Giovanni, Cipolletta Edoardo, Codullo Veronica, Cozzi Franco, Cuomo Giovanna, D’Angelo Salvatore, Dagna Lorenzo, Dall’Ara Francesca, De Andres Ilenia, De Angelis Rossella, De Cata Angelo, De Luca Giacomo, De Santis Maria, Della Rossa Alessandra, Di Vico Claudio, Doveri Marica, Foti Rosario, Furini Federica, Fusaro Enrico, Generali Elena, Gigante Antonietta, Giollo Alessandro, Girelli Francesco, Giuggioli Dilia, Govoni Marcello, Guiducci Serena, Iannone Florenzo, Ingegnoli Francesca, Iuliano Anna Maria, Lazzaroni Maria Grazia, Lubrano Ennio, Lumetti Federica, Magnani Luca, Mennillo Gianna, Murdaca Giuseppe Ospedale, Pagano Mariano Giuseppa, Parisi Simone, Pellegrino Greta, Peroni Clara Lisa, Pigatto Erika, Riccieri Valeria, Romeo Nicoletta, Rosato Edoardo, Sambataro Gianluca, Saracco Marta, Sebastiani Giandomenico, Spinella Amelia, Talotta Rossella, Visalli Elisa, Vultaggio Licia, Zanatta Elisabetta, and Zanframundo Giovanni

Subjects
Medicine
Abstract

Objective To describe demographic, clinical and laboratory features of systemic sclerosis sine scleroderma (ssSSc) in a large multicentre systemic sclerosis (SSc) cohort.Methods Data involving 1808 SSc patients from Italian Systemic sclerosis PRogression INvestiGation registry were collected. The ssSSc was defined by the absence of any cutaneous sclerosis and/or puffy fingers. Clinical and serological features of ssSSc were compared with limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) subsets.Results Among patients with SSc, only 61 (3.4%) were classified as having ssSSc (F/M=19/1). Time from Raynaud’s phenomenon (RP) onset to diagnosis was longer in ssSSc (3 years, IQR 1–16.5) than lcSSc (2 years, IQR 0–7), and dcSSc (1 year, IQR 0–3) (p

Published
2023
Full Text
View/download PDF

4. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Author

Ferri, Clodoveo, Raimondo, Vincenzo, Giuggioli, Dilia, Gragnani, Laura, Lorini, Serena, Dagna, Lorenzo, Bosello, Silvia Laura, Foti, Rosario, Riccieri, Valeria, Guiducci, Serena, Cuomo, Giovanna, Tavoni, Antonio, De Angelis, Rossella, Cacciapaglia, Fabio, Zanatta, Elisabetta, Cozzi, Franco, Murdaca, Giuseppe, Cavazzana, Ilaria, Romeo, Nicoletta, Codullo, Veronica, Pellegrini, Roberta, Varcasia, Giuseppe, De Santis, Maria, Selmi, Carlo, Abignano, Giuseppina, Caminiti, Maurizio, L'Andolina, Massimo, Olivo, Domenico, Lubrano, Ennio, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Ruscitti, Piero, Urraro, Teresa, Visentini, Marcella, Bellando-Randone, Silvia, Visalli, Elisa, Testa, Davide, Sciascia, Gabriella, Masini, Francesco, Pellegrino, Greta, Saccon, Francesca, Balestri, Eugenia, Elia, Giusy, Ferrari, Silvia Martina, Tonutti, Antonio, Dall’Ara, Francesca, Pagano Mariano, Giuseppa, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Dal Bosco, Ylenia, Foti, Roberta, Di Cola, Ilenia, Scorpiniti, Daniela, Fusaro, Enrico, Ferrari, Tommaso, Gigliotti, Pietro, Campochiaro, Corrado, Francioso, Francesca, Iandoli, Carlo, Caira, Virginia, Zignego, Anna Linda, D'Angelo, Salvatore, Franceschini, Franco, Matucci-Cerinic, Marco, Giacomelli, Roberto, Doria, Andrea, Santini, Stefano Angelo, Fallahi, Poupak, Iannone, Florenzo, and Antonelli, Alessandro

Published
2023
Full Text
View/download PDF

5. Apremilast retention rate in clinical practice: observations from an Italian multi-center study

Author

Ariani, Alarico, Parisi, Simone, Del Medico, Patrizia, Farina, Antonella, Visalli, Elisa, Molica Colella, Aldo Biagio, Lumetti, Federica, Caccavale, Rosalba, Scolieri, Palma, Andracco, Romina, Girelli, Francesco, Bravi, Elena, Colina, Matteo, Volpe, Alessandro, Ianniello, Aurora, Franchina, Veronica, Platè, Ilaria, Di Donato, Eleonora, Amato, Giorgio, Salvarani, Carlo, Lucchini, Gianluca, De Lucia, Francesco, Molica Colella, Francesco, Santilli, Daniele, Ferrero, Giulio, Marchetta, Antonio, Arrigoni, Eugenio, Mozzani, Flavio, Foti, Rosario, Sandri, Gilda, Bruzzese, Vincenzo, Paroli, Marino, Fusaro, Enrico, and Becciolini, Andrea

Published
2022
Full Text
View/download PDF

6. Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature

Author

Ferri, Clodoveo, De Angelis, Rossella, Giuggioli, Dilia, Bajocchi, Gianluigi, Dagna, Lorenzo, Zanframundo, Giovanni, Foti, Rosario, Cacciapaglia, Fabio, Cuomo, Giovanna, Ariani, Alarico, Rosato, Edoardo, Guiducci, Serena, Girelli, Francesco, Riccieri, Valeria, Zanatta, Elisabetta, Bosello, Silvia, Cavazzana, Ilaria, Ingegnoli, Francesca, De Santis, Maria, Murdaca, Giuseppe, Abignano, Giuseppina, Romeo, Nicoletta, Della Rossa, Alessandra, Caminiti, Maurizio, Iuliano, Annamaria, Ciano, Giovanni, Beretta, Lorenzo, Bagnato, Gianluca, Lubrano, Ennio, De Andres, Ilenia, Giollo, Alessandro, Saracco, Marta, Agnes, Cecilia, Lumetti, Federica, Spinella, Amelia, Magnani, Luca, Campochiaro, Corrado, De Luca, Giacomo, Codullo, Veronica, Visalli, Elisa, Masini, Francesco, Gigante, Antonietta, Bellando-Randone, Silvia, Pellegrino, Greta, Pigatto, Erika, Lazzaroni, Maria Grazia, Franceschini, Franco, Generali, Elena, Mennillo, Gianna, Barsotti, Simone, Mariano, Giuseppa Pagano, Calabrese, Francesca, Furini, Federica, Vultaggio, Licia, Parisi, Simone, Peroni, Clara Lisa, Rozza, Davide, Zanetti, Anna, Carrara, Greta, Landolfi, Giampiero, Scirè, Carlo Alberto, Bianchi, Gerolamo, Fusaro, Enrico, Sebastiani, Gian Domenico, Govoni, Marcello, D'Angelo, Salvatore, Cozzi, Franco, Doria, Andrea, Iannone, Florenzo, Salvarani, Carlo, and Matucci-Cerinic, Marco

Published
2022
Full Text
View/download PDF

7. Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases

Author

Ursini, Francesco, Ruscitti, Piero, Raimondo, Vincenzo, De Angelis, Rossella, Cacciapaglia, Fabio, Pigatto, Erika, Olivo, Domenico, Di Cola, Ilenia, Galluccio, Felice, Francioso, Francesca, Foti, Rosario, Tavoni, Antonio Gaetano, D’Angelo, Salvatore, Campochiaro, Corrado, Motta, Francesca, De Santis, Maria, Bilia, Silvia, Bruno, Caterina, De Luca, Giacomo, Visentini, Marcella, Ciaffi, Jacopo, Mancarella, Luana, Brusi, Veronica, D’Onghia, Martina, Cuomo, Giovanna, Fusaro, Enrico, Cipriani, Paola, Dagna, Lorenzo, Guiducci, Serena, Meliconi, Riccardo, Iannone, Florenzo, Iagnocco, Annamaria, Giacomelli, Roberto, and Ferri, Clodoveo

Published
2022
Full Text
View/download PDF

9. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study

Author

Colombo, Delia, Frassi, Micol, Pagano Mariano, Giusy, Fusaro, Enrico, Lomater, Claudia, Del Medico, Patrizia, Iannone, Florenzo, Foti, Rosario, Limonta, Massimiliano, Marchesoni, Antonio, Raffeiner, Bernd, Viapiana, Ombretta, Grassi, Walter, Grembiale, Rosa Daniela, Guggino, Giuliana, Mazzone, Antonino, Tirri, Enrico, Perricone, Roberto, Sarzi Puttini, Pier Carlo, De Vita, Salvatore, Conti, Fabrizio, Ori, Alessandra, Simoni, Lucia, Fiocchi, Martina, Orsenigo, Roberto, and Zagni, Emanuela

Published
2022
Full Text
View/download PDF

10. A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study

Author

Zagni, Emanuela, Frassi, Micol, Mariano, Giuseppa Pagano, Fusaro, Enrico, Lomater, Claudia, Del Medico, Patrizia, Iannone, Florenzo, Foti, Rosario, Limonta, Massimiliano, Marchesoni, Antonio, Raffeiner, Bernd, Viapiana, Ombretta, Grassi, Walter, Grembiale, Rosa Daniela, Guggino, Giuliana, Mazzone, Antonino, Tirri, Enrico, Perricone, Roberto, Sarzi Puttini, Pier Carlo, De Vita, Salvatore, Conti, Fabrizio, Zullo, Alessandro, Simoni, Lucia, Fiocchi, Martina, Orsenigo, Roberto, and Colombo, Delia

Published
2022
Full Text
View/download PDF

11. Joint Diseases

Author

Robba, Tiziana, Tosco, Paolo, Parisi, Simone, Ramieri, Guglielmo, Fusaro, Enrico, Faletti, Riccardo, Tanteri, Giulia, Robba, Tiziana, editor, Tanteri, Carlotta, editor, and Tanteri, Giulia, editor

Published
2020
Full Text
View/download PDF

13. Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A case-control study from the Italian national multicenter 'SPRING' (Systemic Sclerosis Progression InvestiGation) Registry

Author

Riccieri, Valeria, Pellegrino, Greta, Cipolletta, Edoardo, Giuggioli, Dilia, Bajocchi, Gianluigi, Bellando-Randone, Silvia, Dagna, Lorenzo, Zanframundo, Giovanni, Foti, Rosario, Cacciapaglia, Fabio, Cuomo, Giovanna, Ariani, Alarico, Rosato, Edoardo, Lepri, Gemma, Girelli, Francesco, Zanatta, Elisabetta, Bosello, Silvia Laura, Cavazzana, Ilaria, Ingegnoli, Francesca, De Santis, Maria, Murdaca, Giuseppe, Abignano, Giuseppina, Romeo, Nicoletta, Della Rossa, Alessandra, Caminiti, Maurizio, Iuliano, Annamaria, Ciano, Giovanni, Beretta, Lorenzo, Bagnato, Gianluca, Lubrano, Ennio, De Andres, Ilenia, Giollo, Alessandro, Saracco, Marta, Agnes, Cecilia, Lumetti, Federica, Spinella, Amelia, Magnani, Luca, Campochiaro, Corrado, De Luca, Giacomo, Codullo, Veronica, Visalli, Elisa, Di Vico, Claudio, Gigante, Antonietta, Saccon, Francesca, Grazia Lazzaroni, Maria, Franceschini, Franco, Generali, Elena, Mennillo, Gianna, Barsotti, Simone, Pagano Mariano, Giuseppa, Calabrese, Francesca, Furini, Federica, Vultaggio, Licia, Parisi, Simone, Peroni, Clara Lisa, Bianchi, Gerolamo, Conti, Fabrizio, Cozzi, Franco, D'Angelo, Salvatore, Doria, Andrea, Fusaro, Enrico, Govoni, Marcello, Guiducci, Serena, Iannone, Florenzo, Salvarani, Carlo, Sebastiani, Gian Domenico, Ferri, Clodoveo, Matucci-Cerinic, Marco, De Angelis, Rossella, Bosello, Silvia Laura (ORCID:0000-0002-4837-447X), Riccieri, Valeria, Pellegrino, Greta, Cipolletta, Edoardo, Giuggioli, Dilia, Bajocchi, Gianluigi, Bellando-Randone, Silvia, Dagna, Lorenzo, Zanframundo, Giovanni, Foti, Rosario, Cacciapaglia, Fabio, Cuomo, Giovanna, Ariani, Alarico, Rosato, Edoardo, Lepri, Gemma, Girelli, Francesco, Zanatta, Elisabetta, Bosello, Silvia Laura, Cavazzana, Ilaria, Ingegnoli, Francesca, De Santis, Maria, Murdaca, Giuseppe, Abignano, Giuseppina, Romeo, Nicoletta, Della Rossa, Alessandra, Caminiti, Maurizio, Iuliano, Annamaria, Ciano, Giovanni, Beretta, Lorenzo, Bagnato, Gianluca, Lubrano, Ennio, De Andres, Ilenia, Giollo, Alessandro, Saracco, Marta, Agnes, Cecilia, Lumetti, Federica, Spinella, Amelia, Magnani, Luca, Campochiaro, Corrado, De Luca, Giacomo, Codullo, Veronica, Visalli, Elisa, Di Vico, Claudio, Gigante, Antonietta, Saccon, Francesca, Grazia Lazzaroni, Maria, Franceschini, Franco, Generali, Elena, Mennillo, Gianna, Barsotti, Simone, Pagano Mariano, Giuseppa, Calabrese, Francesca, Furini, Federica, Vultaggio, Licia, Parisi, Simone, Peroni, Clara Lisa, Bianchi, Gerolamo, Conti, Fabrizio, Cozzi, Franco, D'Angelo, Salvatore, Doria, Andrea, Fusaro, Enrico, Govoni, Marcello, Guiducci, Serena, Iannone, Florenzo, Salvarani, Carlo, Sebastiani, Gian Domenico, Ferri, Clodoveo, Matucci-Cerinic, Marco, De Angelis, Rossella, and Bosello, Silvia Laura (ORCID:0000-0002-4837-447X)

Abstract

Background: Intravenous iloprost has been widely used for the treatment of systemic sclerosis peripheral vasculopathy. No agreement has been found on the regimen and the dosage of intravenous iloprost in different scleroderma subset conditions. This study aimed to evaluate the modalities of intravenous iloprost administration within a large cohort of systemic sclerosis patients from the SPRING Registry and to identify any associated clinical-demographic, instrumental or therapeutic data. Patients and methods: Data of systemic sclerosis patients treated with intravenous iloprost for at least 1 year (case group) were retrospectively analyzed, including different timing and duration of intravenous iloprost session, and compared with those of untreated patients (control group). Results: Out of 1895 analyzed patients, 937 (49%) received intravenous iloprost treatment, while 958 (51%) were assigned to the control group. Among cases, about 70% were treated every 4 weeks, 24% with an interval of more than 4 weeks, and only 6% of less than 4 weeks. Most patients receiving the treatment every 4 weeks, or less, underwent infusion cycle for 1 day only, while if it was scheduled with an interval of more than 4 weeks, a total number of 5 consecutive days of infusions was the preferred regimen. The comparison between the two groups revealed that patients treated with intravenous iloprost had a higher frequency of DUs (p < 0.001), pitting scars (p < 0.001), diffuse cutaneous involvement (p < 0.001), interstitial lung disease (p < 0.002), as well as higher rates of anti-topoisomerase I, "late" scleroderma pattern at nailfold videocapillaroscopy. These findings were confirmed by multivariate analysis. Conclusion: Our data provide a picture on the Italian use of intravenous iloprost among systemic sclerosis patients and showed that it was usually employed in patients with a more aggressive spectrum of the disease. The disparity of intravenous iloprost treatment strategies

Published
2024

18. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study

Author

Bartoloni, Elena, Gonzalez-Gay, Miguel A., Scirè, Carlo, Castaneda, Santos, Gerli, Roberto, Lopez-Longo, Francisco Javier, Martinez-Barrio, Julia, Govoni, Marcello, Furini, Federica, Pina, Trinitario, Iannone, Florenzo, Giannini, Margherita, Nuño, Laura, Quartuccio, Luca, Ortego-Centeno, Norberto, Alunno, Alessia, Specker, Christopher, Montecucco, Carlomaurizio, Triantafyllias, Konstantinos, Balduzzi, Silvia, Sifuentes-Giraldo, Walter Alberto, Paolazzi, Giuseppe, Bravi, Elena, Schwarting, Andreas, Pellerito, Raffaele, Russo, Alessandra, Selmi, Carlo, Saketkoo, Lesley-Ann, Fusaro, Enrico, Parisi, Simone, Pipitone, Nicolò, Franceschini, Franco, Cavazzana, Ilaria, Neri, Rossella, Barsotti, Simone, Codullo, Veronica, and Cavagna, Lorenzo

Published
2017
Full Text
View/download PDF

20. Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study

Author

Paroli, Marino, primary, Becciolini, Andrea, additional, Bravi, Elena, additional, Andracco, Romina, additional, Nucera, Valeria, additional, Parisi, Simone, additional, Ometto, Francesca, additional, Lumetti, Federica, additional, Farina, Antonella, additional, Del Medico, Patrizia, additional, Colina, Matteo, additional, Lo Gullo, Alberto, additional, Ravagnani, Viviana, additional, Scolieri, Palma, additional, Larosa, Maddalena, additional, Priora, Marta, additional, Visalli, Elisa, additional, Addimanda, Olga, additional, Vitetta, Rosetta, additional, Volpe, Alessandro, additional, Bezzi, Alessandra, additional, Girelli, Francesco, additional, Molica Colella, Aldo Biagio, additional, Caccavale, Rosalba, additional, Di Donato, Eleonora, additional, Adorni, Giuditta, additional, Santilli, Daniele, additional, Lucchini, Gianluca, additional, Arrigoni, Eugenio, additional, Platè, Ilaria, additional, Mansueto, Natalia, additional, Ianniello, Aurora, additional, Fusaro, Enrico, additional, Ditto, Maria Chiara, additional, Bruzzese, Vincenzo, additional, Camellino, Dario, additional, Bianchi, Gerolamo, additional, Serale, Francesca, additional, Foti, Rosario, additional, Amato, Giorgio, additional, De Lucia, Francesco, additional, Dal Bosco, Ylenia, additional, Foti, Roberta, additional, Reta, Massimo, additional, Fiorenza, Alessia, additional, Rovera, Guido, additional, Marchetta, Antonio, additional, Focherini, Maria Cristina, additional, Mascella, Fabio, additional, Bernardi, Simone, additional, Sandri, Gilda, additional, Giuggioli, Dilia, additional, Salvarani, Carlo, additional, Franchina, Veronica, additional, Molica Colella, Francesco, additional, Ferrero, Giulio, additional, and Ariani, Alarico, additional

Published
2023
Full Text
View/download PDF

21. Management of psoriatic arthritis: a consensus opinion by expert rheumatologists

Author

D'Angelo, Salvatore, Atzeni, Fabiola, Benucci, Maurizio, Bianchi, Gerolamo, Cantini, Fabrizio, Caporali, Roberto Felice, Carlino, Giorgio, Caso, Francesco, Cauli, Alberto, Ciccia, Francesco, D'Agostino, Maria Antonietta, Dagna, Lorenzo, Dejaco, Christian, Epis, Oscar Massimiliano, Ferrucci, Maria Grazia, Franceschini, Franco, Fusaro, Enrico, Gabini, Marco, Gerli, Roberto, Giacomelli, Roberto, Govoni, Marcello, Gremese, Elisa, Guggino, Giuliana, Iagnocco, Annamaria, Iannone, Florenzo, Laganà, Bruno, Lubrano, Ennio, Montecucco, Carlomaurizio, Peluso, Rosario, Ramonda, Roberta, Rossini, Maurizio, Salvarani, Carlo, Sebastiani, Gian Domenico, Sebastiani, Marco, Selmi, Carlo, Tirri, Enrico, Marchesoni, Antonio, D'Agostino, Maria Antonietta (ORCID:0000-0002-5347-0060), Gremese, Elisa (ORCID:0000-0002-2248-1058), D'Angelo, Salvatore, Atzeni, Fabiola, Benucci, Maurizio, Bianchi, Gerolamo, Cantini, Fabrizio, Caporali, Roberto Felice, Carlino, Giorgio, Caso, Francesco, Cauli, Alberto, Ciccia, Francesco, D'Agostino, Maria Antonietta, Dagna, Lorenzo, Dejaco, Christian, Epis, Oscar Massimiliano, Ferrucci, Maria Grazia, Franceschini, Franco, Fusaro, Enrico, Gabini, Marco, Gerli, Roberto, Giacomelli, Roberto, Govoni, Marcello, Gremese, Elisa, Guggino, Giuliana, Iagnocco, Annamaria, Iannone, Florenzo, Laganà, Bruno, Lubrano, Ennio, Montecucco, Carlomaurizio, Peluso, Rosario, Ramonda, Roberta, Rossini, Maurizio, Salvarani, Carlo, Sebastiani, Gian Domenico, Sebastiani, Marco, Selmi, Carlo, Tirri, Enrico, Marchesoni, Antonio, D'Agostino, Maria Antonietta (ORCID:0000-0002-5347-0060), and Gremese, Elisa (ORCID:0000-0002-2248-1058)

Abstract

BackgroundPsoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease involving several articular and extra-articular structures. Despite the important progresses recently made in all of the aspects of this disease, its management is still burdened by unresolved issues. The aim of this exercise was to provide a set of statements that may be helpful for the management of PsA.MethodsA group of 38 Italian rheumatologists with recognized expertise in PsA selected and addressed the following four topics: "early PsA," "axial-PsA," "extra-articular manifestations and comorbidities," "therapeutic goals." Relevant articles from the literature (2016-2022) were selected by the experts based on a PubMed search. A number of statements for each topic were elaborated.ResultsNinety-four articles were selected and evaluated, 68 out of the 1,114 yielded by the literature search and 26 added by the Authors. Each of the four topic was subdivided in themes as follows: transition from psoriasis to PsA, imaging vs. CASPAR criteria in early diagnosis, early treatment for "early PsA"; axial-PsA vs. axialspondyloarthritis, diagnosis, clinical evaluation, treatment, standard radiography vs. magnetic resonance imaging for "axial PsA"; influence of inflammatory bowel disease on the therapeutic choice, cardiovascular comorbidity, bone damage, risk of infection for "comorbidities and extra-articular manifestations"; target and tools, treat-to-target strategy, role of imaging for "therapeutic goals." The final document consisted of 49 statements.DiscussionThe final product of this exercise is a set of statements concerning the main issues of PsA management offering an expert opinion for some unmet needs of this complex disease.

Published
2023

22. Efficacy and Safety of Upadacitinib in Rheumatoid Arthritis: Real-Life Experience from a Prospective Longitudinal Multicentric Study.

Author

Baldi, Caterina, Parisi, Simone, Falsetti, Paolo, Sota, Jurgen, Ditto, Maria Chiara, Capassoni, Marco, D'alessandro, Miriana, Conticini, Edoardo, Nacci, Francesca, Peroni, Clara Lisa, Cometi, Laura, Fusaro, Enrico, Frediani, Bruno, and Guiducci, Serena

Subjects
RHEUMATOID arthritis, VARICELLA-zoster virus, VENOUS thrombosis, LONGITUDINAL method, VIRUS diseases
Abstract

Background: We provide the first prospective longitudinal multicenter experience on Upadacitinib efficacy and safety profile in Rheumatoid Arthritis (RA) in a real-life context, focusing on clinimetric and ultrasonographic (US) data. Methods: RA patients referred to three Italian tertiary Centers who started Upadacitinib were enrolled as per ACR/EULAR classification criteria and prospectively reviewed. The primary aim of this study was to assess changes in clinimetric and ultrasonographic scores through time (at baseline, after 1 month, 3 months, and 6 months from the beginning of the therapy). Secondary aims were to: (i) estimate the impact of biologic lines of treatment and concomitant therapies on response to therapy; (ii) explore changes in laboratory parameters; and (iii) find potential predictive factors associated with response to therapy. Results: Seventy-one patients (49 Females and 22 Males) were included. Clinimetric scores, including the Disease Activity Score (DAS28-CRP) and Simplified Clinical Disease Activity Index (SDAI), and US findings (synovial hypertrophy and power Doppler) significantly improved (p = 0.029, p = 0.001, p = 0.001, p = 0.001, respectively). Regression analysis revealed a significant association between the concomitant csDMARDs therapy at baseline and the lack of improvement in synovial hypertrophy [OR −4.824, p = 0.010] as well as with DAS28-CRP [OR −0.690, p = 0.045], whereas the presence of increased ESR or CRP at baseline was able to predict a significant improvement in SDAI [OR 8.481, p = 0.003]. No adverse events, such as deep venous thrombosis, pulmonary embolism, or herpes zoster virus infection, were reported during this study observation. Conclusion: Our real-life experience confirms the efficacy of Upadacitinib in terms of clinical and ultrasonographic improvement, as well as displaying a good safety profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study

Author

Lo Gullo, Alberto, primary, Becciolini, Andrea, additional, Parisi, Simone, additional, Del Medico, Patrizia, additional, Farina, Antonella, additional, Visalli, Elisa, additional, Dal Bosco, Ylenia, additional, Molica Colella, Aldo, additional, Lumetti, Federica, additional, Caccavale, Rosalba, additional, Scolieri, Palma, additional, Andracco, Romina, additional, Girelli, Francesco, additional, Bravi, Elena, additional, Colina, Matteo, additional, Volpe, Alessandro, additional, Ianniello, Aurora, additional, Ditto, Maria, additional, Nucera, Valeria, additional, Franchina, Veronica, additional, Platé, Ilaria, additional, Di Donato, Eleonora, additional, Amato, Giorgio, additional, Salvarani, Carlo, additional, Bernardi, Simone, additional, Lucchini, Gianluca, additional, De Lucia, Francesco, additional, Molica Colella, Francesco, additional, Santilli, Daniele, additional, Mansueto, Natalia, additional, Ferrero, Giulio, additional, Marchetta, Antonio, additional, Arrigoni, Eugenio, additional, Foti, Rosario, additional, Sandri, Gilda, additional, Bruzzese, Vincenzo, additional, Paroli, Marino, additional, Fusaro, Enrico, additional, and Ariani, Alarico, additional

Published
2023
Full Text
View/download PDF

27. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry ‘SPRING’ of the Italian Society for Rheumatology

Author

De Angelis, Rossella, primary, Ferri, Clodoveo, additional, Giuggioli, Dilia, additional, Bajocchi, Gianluigi, additional, Dagna, Lorenzo, additional, Bellando-Randone, Silvia, additional, Zanframundo, Giovanni, additional, Foti, Rosario, additional, Cacciapaglia, Fabio, additional, Cuomo, Giovanna, additional, Ariani, Alarico, additional, Rosato, Edoardo, additional, Lepri, Gemma, additional, Girelli, Francesco, additional, Riccieri, Valeria, additional, Zanatta, Elisabetta, additional, Bosello, Silvia Laura, additional, Cavazzana, Ilaria, additional, Ingegnoli, Francesca, additional, De Santis, Maria, additional, Murdaca, Giuseppe, additional, Abignano, Giuseppina, additional, Romeo, Nicoletta, additional, Della Rossa, Alessandra, additional, Caminiti, Maurizio, additional, Iuliano, Anna Maria, additional, Ciano, Giovanni, additional, Beretta, Lorenzo, additional, Bagnato, Gianluca, additional, Lubrano, Ennio, additional, De Andres, Ilenia, additional, Giollo, Alessandro, additional, Saracco, Marta, additional, Agnes, Cecilia, additional, Cipolletta, Edoardo, additional, Lumetti, Federica, additional, Spinella, Amelia, additional, Magnani, Luca, additional, Campochiaro, Corrado, additional, De Luca, Giacomo, additional, Codullo, Veronica, additional, Visalli, Elisa, additional, Di Vico, Claudio, additional, Gigante, Antonietta, additional, Pellagrino, Greta, additional, Pigatto, Erika, additional, Lazzaroni, Maria-Grazia, additional, Franceschini, Franco, additional, Generali, Elena, additional, Mennillo, Gianna, additional, Barsotti, Simone, additional, Mariano, Giuseppa Pagano, additional, Furini, Federica, additional, Vultaggio, Licia, additional, Parisi, Simone, additional, Peroni, Clara Lisa, additional, Rozza, Davide, additional, Zanetti, Anna, additional, Carrara, Greta, additional, Landolfi, Gianpiero, additional, Scirè, Carlo Alberto, additional, Bianchi, Gerolamo, additional, Fusaro, Enrico, additional, Sebastiani, Gian Domenico, additional, Govoni, Marcello, additional, D'Angelo, Salvatore, additional, Cozzi, Franco, additional, Guiducci, Serena, additional, Doria, Andrea, additional, Salvarani, Carlo, additional, Iannone, Florenzo, additional, and Matucci-Cerinic, Marco, additional

Published
2023
Full Text
View/download PDF

29. Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study

Author

Becciolini, Andrea, primary, Parisi, Simone, additional, Del Medico, Patrizia, additional, Farina, Antonella, additional, Visalli, Elisa, additional, Molica Colella, Aldo Biagio, additional, Lumetti, Federica, additional, Caccavale, Rosalba, additional, Scolieri, Palma, additional, Andracco, Romina, additional, Girelli, Francesco, additional, Bravi, Elena, additional, Colina, Matteo, additional, Volpe, Alessandro, additional, Ianniello, Aurora, additional, Ditto, Maria Chiara, additional, Nucera, Valeria, additional, Franchina, Veronica, additional, Platè, Ilaria, additional, Donato, Eleonora Di, additional, Amato, Giorgio, additional, Salvarani, Carlo, additional, Bernardi, Simone, additional, Lucchini, Gianluca, additional, De Lucia, Francesco, additional, Molica Colella, Francesco, additional, Santilli, Daniele, additional, Mansueto, Natalia, additional, Ferrero, Giulio, additional, Marchetta, Antonio, additional, Arrigoni, Eugenio, additional, Foti, Rosario, additional, Sandri, Gilda, additional, Bruzzese, Vincenzo, additional, Paroli, Marino, additional, Fusaro, Enrico, additional, and Ariani, Alarico, additional

Published
2023
Full Text
View/download PDF

30. Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group

Author

Cavagna, Lorenzo, Nuño, Laura, Scirè, Carlo Alberto, Govoni, Marcello, Longo, Francisco Javier Lopez, Franceschini, Franco, Neri, Rossella, Castañeda, Santos, Sifuentes Giraldo, Walter Alberto, Caporali, Roberto, Iannone, Florenzo, Fusaro, Enrico, Paolazzi, Giuseppe, Pellerito, Raffaele, Schwarting, Andreas, Saketkoo, Lesley Ann, Ortego-Centeno, Norberto, Quartuccio, Luca, Bartoloni, Elena, Specker, Christof, Pina Murcia, Trinitario, La Corte, Renato, Furini, Federica, Foschi, Valentina, Bachiller Corral, Javier, Airò, Paolo, Cavazzana, Ilaria, Martínez-Barrio, Julia, Hinojosa, Michelle, Giannini, Margherita, Barsotti, Simone, Menke, Julia, Triantafyllias, Kostantinos, Vitetta, Rosetta, Russo, Alessandra, Bogliolo, Laura, Bajocchi, Gianluigi, Bravi, Elena, Barausse, Giovanni, Bortolotti, Roberto, Selmi, Carlo, Parisi, Simone, Salaffi, Fausto, Montecucco, Carlomaurizio, González-Gay, Miguel Angel, and on Behalf of AENEAS (American and European NEtwork of Antisynthetase Syndrome) Collaborative Group

Published
2017
Full Text
View/download PDF

33. The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A Post Hoc Gender Analysis

Author

Colombo, Delia, Frassi, Micol, Mariano, Giuseppa Pagano, Fusaro, Enrico, Lomater, Claudia, Medico, Patrizia Del, Iannone, Florenzo, Foti, Rosario, Limonta, Massimiliano, Marchesoni, Antonio, Raffeiner, Bernd, Viapiana, Ombretta, Di Carlo, Marco, Grembiale, Rosa Daniela, Guggino, Giuliana, Faggioli, Paola, Tirri, Enrico, Perricone, Roberto, Puttini, Pier Carlo Sarzi, Vita, Salvatore De, Conti, Fabrizio, Rizzoli, Sara, Roncari, Barbara, Fiocchi, Martina, Orsenigo, Roberto, Zagni, Emanuela, Colombo, Delia, Frassi, Micol, Mariano, Giuseppa Pagano, Fusaro, Enrico, Lomater, Claudia, Medico, Patrizia Del, Iannone, Florenzo, Foti, Rosario, Limonta, Massimiliano, Marchesoni, Antonio, Raffeiner, Bernd, Viapiana, Ombretta, Di Carlo, Marco, Grembiale, Rosa Daniela, Guggino, Giuliana, Faggioli, Paola, Tirri, Enrico, Perricone, Roberto, Puttini, Pier Carlo Sarzi, Vita, Salvatore De, Conti, Fabrizio, Rizzoli, Sara, Roncari, Barbara, Fiocchi, Martina, Orsenigo, Roberto, and Zagni, Emanuela

Subjects
psoriatic arthriti, gender difference, observational study, real-world evidence, biologic, effectivene
Abstract

Background: Phenotypic features and outcome differences between sexes have been reported in psoriatic arthritis (PsA). However, little is known about sex differences in effectiveness of biologics in clinical practice. Methods: Post hoc gender analysis of the CHRONOS, a multicenter, noninterventional, retroprospective Italian real-world study assessing 6-month and 1-year effectiveness of biologics for PsA. Results: Eligible patients were 399, 43.1% men. Sociodemographic characteristics, type of arthritis, baseline Disease Activity Score 28 joints (DAS28), and duration of biologic treatment were rather homogeneous. More men were overweight/obese and naive to biologics. The most frequently used biologics were TNF-inhibitors and secukinumab in both sexes. DAS28 responders were 72.7% (women) and 70.5% (men) at 6 months, and 68.0% in both sexes at 1 year. American College of Rheumatology (ACR) response showed a trend for men versus women to achieve more frequently ACR50 (32.6% vs. 26.5% at 6 months; 34.9% vs. 20.0% at 1 year) and ACR70 (22.3% vs. 12.4% at 6 months and 25.0% vs. 13.0% at 1 year). Global satisfaction with treatment at enrollment and after 6 months was slightly higher among men [mean (standard deviation) Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) score: 68.6 (18.6) and 69.9 (18.2), respectively] than women [65.3 (18.2), 66.2 (18.5)]. Conclusions: Overall response to biologics for PsA was rather favorable. With similar baseline disease severity, men appear to have a somewhat earlier and better response with higher treatment satisfaction.

Published
2022

35. Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy

Author

Ditto, Maria Chiara, Parisi, Simone, Varisco, Valentina, Talotta, Rossella, Batticciotto, Alberto, Antivalle, Marco, Gerardi, Maria Chiara, Agosti, Michele, Borrelli, Richard, Fusaro, Enrico, and Sarzi-Puttini, Piercarlo

Subjects
Hepatitis B virus, Hepatitis B Surface Antigens, Immunology, Hepatitis B, Antiviral Agents, Arthritis, Rheumatoid, Biological Therapy, Rheumatology, Prevalence, Humans, Immunology and Allergy, Tumor Necrosis Factor Inhibitors, Virus Activation, Hepatitis B Antibodies
Abstract

Hepatitis B (HBV) is a common comorbidity among rheumatic patients. The prevalence of HBV infection and the rate of reactivation remain unclear. The literature data suggested a higher risk in chronic than in past infection. Currently, the literature data are mostly focused on anti-TNF and rituximab. This retrospective observational study aimed to analyse the prevalence of HBV infection and the risk of viral reactivation in a population of rheumatic patients undergoing anti-TNF and non-anti-TNF agents.We analysed 1216 rheumatic patients, treated with both csDMARDs and bDMARDs between 2006 and 2017. Serologic markers for HBV (HBsAg, anti-HBs, anti-HBc) were performed prior and during biologic treatment. Patients with chronic or resolved infection were monitored every 3 months.The prevalence of HBV in our cohort was 15.7% (chronic infection: 0.4%, resolved infection: 12.6%, anti-HBc positivity alone: 2.6%). 12 (6.2%) out of 191 HBV infected patients experienced a reactivation. All of them showed markers of past infection. One patient experienced HBV reactivation despite lamivudine. Only one patient experienced acute hepatitis, probably due to the interruption of immunosuppressors in anticipation of surgery, not preceded by any HBV prophylactic treatment.HBV reactivation is a rare event in patients treated with a bDMARD and it can also occur while taking lamivudine, not only in chronic carriers (as per the literature data) but also in inactive ones. Regular screening followed by prompt treatment can prevent symptoms or complications. Due to the risk of hepatitis following the immune reconstitution, an antiviral therapy should be considered in the case of sudden discontinuation of csDMARDs or bDMARD.

Published
2021
Full Text
View/download PDF

37. Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

Author

Ferri, Clodoveo, primary, Antonelli, Alessandro, primary, Raimondo, Vincenzo, additional, Gragnani, Laura, additional, Giuggioli, Dilia, additional, Dagna, Lorenzo, additional, Tavoni, Antonio, additional, Ursini, Francesco, additional, L'Andolina, Massimo, additional, Caso, Francesco, additional, Ruscitti, Piero, additional, Caminiti, Maurizio, additional, Foti, Rosario, additional, Riccieri, Valeria, additional, Guiducci, Serena, additional, Pellegrini, Roberta, additional, Zanatta, Elisabetta, additional, Varcasia, Giuseppe, additional, Olivo, Domenico, additional, Gigliotti, Pietro, additional, Cuomo, Giovanna, additional, Murdaca, Giuseppe, additional, Cecchetti, Riccardo, additional, De Angelis, Rossella, additional, Romeo, Nicoletta, additional, Ingegnoli, Francesca, additional, Cozzi, Franco, additional, Codullo, Veronica, additional, Cavazzana, Ilaria, additional, Colaci, Michele, additional, Abignano, Giuseppina, additional, De Santis, Maria, additional, Lubrano, Ennio, additional, Fusaro, Enrico, additional, Spinella, Amelia, additional, Lumetti, Federica, additional, De Luca, Giacomo, additional, Bellando-Randone, Silvia, additional, Visalli, Elisa, additional, Bosco, Ylenia Dal, additional, Amato, Giorgio, additional, Giannini, Daiana, additional, Bilia, Silvia, additional, Masini, Francesco, additional, Pellegrino, Greta, additional, Pigatto, Erika, additional, Generali, Elena, additional, Mariano, Giuseppa Pagano, additional, Pettiti, Giorgio, additional, Zanframundo, Giovanni, additional, Brittelli, Raffaele, additional, Aiello, Vincenzo, additional, Caminiti, Rodolfo, additional, Scorpiniti, Daniela, additional, Ferrari, Tommaso, additional, Campochiaro, Corrado, additional, Brusi, Veronica, additional, Fredi, Micaela, additional, Moschetti, Liala, additional, Cacciapaglia, Fabio, additional, Paparo, Sabrina Rosaria, additional, Ragusa, Francesca, additional, Mazzi, Valeria, additional, Elia, Giusy, additional, Ferrari, Silvia Martina, additional, Di Cola, Ilenia, additional, Vadacca, Marta, additional, Lorusso, Sebastiano, additional, Monti, Monica, additional, Lorini, Serena, additional, Aprile, Maria Letizia, additional, Tasso, Marco, additional, Miccoli, Mario, additional, Bosello, Silvia, additional, D'Angelo, Salvatore, additional, Doria, Andrea, additional, Franceschini, Franco, additional, Meliconi, Riccardo, additional, Matucci-Cerinic, Marco, additional, Iannone, Florenzo, additional, Giacomelli, Roberto, additional, Salvarani, Carlo, additional, Zignego, Anna Linda, additional, and Fallahi, Poupak, additional

Published
2022
Full Text
View/download PDF

38. Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

Author

Ferri, Clodoveo, Raimondo, Vincenzo, Gragnani, Laura, Giuggioli, Dilia, Dagna, Lorenzo, Tavoni, Antonio, Ursini, Francesco, L'Andolina, Massimo, Caso, Francesco, Ruscitti, Piero, Caminiti, Maurizio, Foti, Rosario, Riccieri, Valeria, Guiducci, Serena, Pellegrini, Roberta, Zanatta, Elisabetta, Varcasia, Giuseppe, Olivo, Domenico, Gigliotti, Pietro, Cuomo, Giovanna, Murdaca, Giuseppe, Cecchetti, Riccardo, De Angelis, Rossella, Romeo, Nicoletta, Ingegnoli, Francesca, Cozzi, Franco, Codullo, Veronica, Cavazzana, Ilaria, Colaci, Michele, Abignano, Giuseppina, De Santis, Maria, Lubrano, Ennio, Fusaro, Enrico, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Bellando-Randone, Silvia, Visalli, Elisa, Bosco, Ylenia Dal, Amato, Giorgio, Giannini, Daiana, Bilia, Silvia, Masini, Francesco, Pellegrino, Greta, Pigatto, Erika, Generali, Elena, Mariano, Giuseppa Pagano, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Caminiti, Rodolfo, Scorpiniti, Daniela, Ferrari, Tommaso, Campochiaro, Corrado, Brusi, Veronica, Fredi, Micaela, Moschetti, Liala, Cacciapaglia, Fabio, Paparo, Sabrina Rosaria, Ragusa, Francesca, Mazzi, Valeria, Elia, Giusy, Ferrari, Silvia Martina, Di Cola, Ilenia, Vadacca, Marta, Lorusso, Sebastiano, Monti, Monica, Lorini, Serena, Aprile, Maria Letizia, Tasso, Marco, Miccoli, Mario, Bosello, Silvia Laura, D'Angelo, Salvatore, Doria, Andrea, Franceschini, Franco, Meliconi, Riccardo, Matucci-Cerinic, Marco, Iannone, Florenzo, Giacomelli, Roberto, Salvarani, Carlo, Zignego, Anna Linda, Fallahi, Poupak, Antonelli, Alessandro, Bosello, Silvia (ORCID:0000-0002-4837-447X), Ferri, Clodoveo, Raimondo, Vincenzo, Gragnani, Laura, Giuggioli, Dilia, Dagna, Lorenzo, Tavoni, Antonio, Ursini, Francesco, L'Andolina, Massimo, Caso, Francesco, Ruscitti, Piero, Caminiti, Maurizio, Foti, Rosario, Riccieri, Valeria, Guiducci, Serena, Pellegrini, Roberta, Zanatta, Elisabetta, Varcasia, Giuseppe, Olivo, Domenico, Gigliotti, Pietro, Cuomo, Giovanna, Murdaca, Giuseppe, Cecchetti, Riccardo, De Angelis, Rossella, Romeo, Nicoletta, Ingegnoli, Francesca, Cozzi, Franco, Codullo, Veronica, Cavazzana, Ilaria, Colaci, Michele, Abignano, Giuseppina, De Santis, Maria, Lubrano, Ennio, Fusaro, Enrico, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Bellando-Randone, Silvia, Visalli, Elisa, Bosco, Ylenia Dal, Amato, Giorgio, Giannini, Daiana, Bilia, Silvia, Masini, Francesco, Pellegrino, Greta, Pigatto, Erika, Generali, Elena, Mariano, Giuseppa Pagano, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Caminiti, Rodolfo, Scorpiniti, Daniela, Ferrari, Tommaso, Campochiaro, Corrado, Brusi, Veronica, Fredi, Micaela, Moschetti, Liala, Cacciapaglia, Fabio, Paparo, Sabrina Rosaria, Ragusa, Francesca, Mazzi, Valeria, Elia, Giusy, Ferrari, Silvia Martina, Di Cola, Ilenia, Vadacca, Marta, Lorusso, Sebastiano, Monti, Monica, Lorini, Serena, Aprile, Maria Letizia, Tasso, Marco, Miccoli, Mario, Bosello, Silvia Laura, D'Angelo, Salvatore, Doria, Andrea, Franceschini, Franco, Meliconi, Riccardo, Matucci-Cerinic, Marco, Iannone, Florenzo, Giacomelli, Roberto, Salvarani, Carlo, Zignego, Anna Linda, Fallahi, Poupak, Antonelli, Alessandro, and Bosello, Silvia (ORCID:0000-0002-4837-447X)

Abstract

Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients. Methods: The study included 3,918 ASD pts (815 M, 3103 F; mean age 59 +/- 12SD years) consecutively recruited between March 2020 and May 2021 at the 36 referral centers of COVID-19 and ASD Italian Study Group. The possible development of COVID-19 was recorded by means of a telephone survey using a standardized symptom assessment questionnaire. Results: ASD patients showed a significantly higher prevalence of COVID-19 (8.37% vs. 6.49%; p<0.0001) but a death rate statistically comparable to the Italian general population (3.65% vs. 2.95%). Among the 328 ASD patients developing COVID-19, 17% needed hospitalization, while mild-moderate manifestations were observed in 83% of cases. Moreover, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular events; systemic sclerosis (SSc) patients showed a significantly higher COVID-19-related death rate compared to the general population (6.29% vs. 2.95%; p=0.018). Major adverse prognostic factors to develop COVID-19 were: older age, male gender, SSc, pre-existing ASD-related interstitial lung involvement, and long-term steroid treatment. Of note, patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) showed a significantly lower prevalence of COVID-19 compared to those without (3.58% vs. 46.99%; p=0.000), as well as the SSc patients treated with low dose aspirin (with 5.57% vs. without 27.84%; p=0.000). Conclusion: During the first three pandemic waves, ASD patients showed a death rate comparable to the general population despite the significantly higher prevalence of COVID-19. A significantly increased COVID-19-related mortality was recorded in only SSc patients' subgroup, possibly favored

Published
2022

39. Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology

Author

De Angelis, Rossella, Giuggioli, Dilia, Bajocchi, Gianluigi, Dagna, Lorenzo, Zanframundo, Giovanni, Foti, Rosario, Cacciapaglia, Fabio, Cuomo, Giovanna, Ariani, Alarico, Rosato, Edoardo, Guiducci, Serena, Girelli, Francesco, Riccieri, Valeria, Zanatta, Elisabetta, Bosello, Silvia Laura, Cavazzana, Ilaria, Ingegnoli, Francesca, Santis, Maria De, Murdaca, Giuseppe, Abignano, Giuseppina, Romeo, Nicoletta, Della Rossa, Alessandra, Caminiti, Maurizio, Iuliano, Annamaria, Ciano, Giovanni, Beretta, Lorenzo, Bagnato, Gianluca, Lubrano, Ennio, De Andres, Ilenia, Giollo, Alessandro, Saracco, Marta, Agnes, Cecilia, Lumetti, Federica, Spinella, Amelia, Magnani, Luca, Campochiaro, Corrado, De Luca, Giacomo, Codullo, Veronica, Visalli, Elisa, Masini, Francesco, Gigante, Antonietta, Bellando-Randone, Silvia, Pellegrino, Greta, Pigatto, Erika, Dall'Ara, Francesca, Lazzaroni, Maria Grazia, Generali, Elena, Mennillo, Gianna, Barsotti, Simone, Mariano, Giuseppa Pagano, Calabrese, Francesca, Furini, Federica, Vultaggio, Licia, Parisi, Simone, Peroni, Clara Lisa, Risa, Anna Maria, Rozza, Davide, Zanetti, Anna, Carrara, Greta, Landolfi, Giampiero, Scirè, Carlo Alberto, Bianchi, Gerolamo, Fusaro, Enrico, Sebastiani, Gian Domenico, Govoni, Marcello, D'Angelo, Salvatore, Cozzi, Franco, Doria, Andrea, Iannone, Florenzo, Salvarani, Carlo, Matucci-Cerinic, Marco, Ferri, Clodoveo, Bosello, Silvia (ORCID:0000-0002-4837-447X), De Angelis, Rossella, Giuggioli, Dilia, Bajocchi, Gianluigi, Dagna, Lorenzo, Zanframundo, Giovanni, Foti, Rosario, Cacciapaglia, Fabio, Cuomo, Giovanna, Ariani, Alarico, Rosato, Edoardo, Guiducci, Serena, Girelli, Francesco, Riccieri, Valeria, Zanatta, Elisabetta, Bosello, Silvia Laura, Cavazzana, Ilaria, Ingegnoli, Francesca, Santis, Maria De, Murdaca, Giuseppe, Abignano, Giuseppina, Romeo, Nicoletta, Della Rossa, Alessandra, Caminiti, Maurizio, Iuliano, Annamaria, Ciano, Giovanni, Beretta, Lorenzo, Bagnato, Gianluca, Lubrano, Ennio, De Andres, Ilenia, Giollo, Alessandro, Saracco, Marta, Agnes, Cecilia, Lumetti, Federica, Spinella, Amelia, Magnani, Luca, Campochiaro, Corrado, De Luca, Giacomo, Codullo, Veronica, Visalli, Elisa, Masini, Francesco, Gigante, Antonietta, Bellando-Randone, Silvia, Pellegrino, Greta, Pigatto, Erika, Dall'Ara, Francesca, Lazzaroni, Maria Grazia, Generali, Elena, Mennillo, Gianna, Barsotti, Simone, Mariano, Giuseppa Pagano, Calabrese, Francesca, Furini, Federica, Vultaggio, Licia, Parisi, Simone, Peroni, Clara Lisa, Risa, Anna Maria, Rozza, Davide, Zanetti, Anna, Carrara, Greta, Landolfi, Giampiero, Scirè, Carlo Alberto, Bianchi, Gerolamo, Fusaro, Enrico, Sebastiani, Gian Domenico, Govoni, Marcello, D'Angelo, Salvatore, Cozzi, Franco, Doria, Andrea, Iannone, Florenzo, Salvarani, Carlo, Matucci-Cerinic, Marco, Ferri, Clodoveo, and Bosello, Silvia (ORCID:0000-0002-4837-447X)

Abstract

Objective. There is still a great deal to learn about the influence of sex in systemic sclerosis (SSc). In this respect, national registries provide large and homogeneous patient cohorts for analytical studies. We therefore investigated a wide-ranging and well-characterized SSc series with the aim of identifying sex differences in disease expression, with a special focus on demographic, clinical, and serological characteristics.Methods. A multicenter SSc cohort of 2281 patients, including 247 men, was recruited in the Italian Systemic sclerosis PRogression INvestiGation (SPRING) registry. Demographic data, disease manifestations, serological profile, and internal organ involvement were compared.Results. The overall female/male ratio was 8.2:1. Female/male ratios for limited cutaneous SSc, diffuse cutaneous SSc, and SSc sine scleroderma subsets were 8.7:1, 4.9:1, and 10.7:1, respectively. A shorter time from onset of Raynaud phenomenon to SSc diagnosis, an increased prevalence of the diffuse cutaneous subset, renal crisis, and digital ulcers were found in males, whereas a significantly higher percentage of sicca syndrome, serum antinuclear antibodies, antiextractable nuclear antigens, anti-La/SSB, and anticentromere protein B was detected in the female group. Males exhibited lower left ventricular ejection fraction, as well as higher prevalence of conduction blocks, arrhythmias, ground glass, and honeycombing. Moreover, forced vital capacity and total lung capacity were medially lower in men than in women. Finally, males were more frequently treated with immunosuppressive drugs.Conclusion. Our study further supports the presence of several sex-related differences in patients with SSc. These differences were pronounced in the severity of cutaneous, peripheral vascular, and cardiopulmonary involvement for male patients, whereas an increased prevalence of sicca syndrome and a specific autoantibody profile characterized the female sex.

Published
2022

40. Early Spondyloarthritis Clinic: Organizational Improvements in the Patient Journey

Author

D'Angelo, Salvatore, Afeltra, Antonella, Atzeni, Fabiola, Baldissera, Elena, Caminiti, Maurizio, Ciccia, Francesco, D'Agostino, Maria Antonietta, Dagna, Lorenzo, Erre, Gian Luca, Franceschini, Franco, Fusaro, Enrico, Giacomelli, Roberto, Gremese, Elisa, Guggino, Giuliana, Lomater, Claudia, Lubrano, Ennio, Padula, Angela Anna, Pagano Mariano, Giuseppa, Russo, Romualdo, Sarzi Puttini, Piercarlo, Scarpa, Raffaele, Selmi, Carlo, Tirri, Enrico, Ferri, Stefano, Iannone, Florenzo, D'Agostino, Maria Antonietta (ORCID:0000-0002-5347-0060), Gremese, Elisa (ORCID:0000-0002-2248-1058), D'Angelo, Salvatore, Afeltra, Antonella, Atzeni, Fabiola, Baldissera, Elena, Caminiti, Maurizio, Ciccia, Francesco, D'Agostino, Maria Antonietta, Dagna, Lorenzo, Erre, Gian Luca, Franceschini, Franco, Fusaro, Enrico, Giacomelli, Roberto, Gremese, Elisa, Guggino, Giuliana, Lomater, Claudia, Lubrano, Ennio, Padula, Angela Anna, Pagano Mariano, Giuseppa, Russo, Romualdo, Sarzi Puttini, Piercarlo, Scarpa, Raffaele, Selmi, Carlo, Tirri, Enrico, Ferri, Stefano, Iannone, Florenzo, D'Agostino, Maria Antonietta (ORCID:0000-0002-5347-0060), and Gremese, Elisa (ORCID:0000-0002-2248-1058)

Abstract

Spondyloarthritis are chronic inflammatory diseases affecting spine, peripheral joints and enthesis, as well as extra-articular sites (bowel, eyes, skin). Diagnosis of spondyloarthritis often is slow and requires a multidisciplinary approach. The "Early SpA Clinic" project aimed at improving the patient care and journeys, by solving some organizational issues existing in Rheumatology Clinics. The "Early SpA Clinic" involved 19 Italian Rheumatology Centers using in-depth organizational analyses to identify areas for improvement. From the results of the analyses, some organizational solutions were suggested, and their impact measured at the end of the project through specific KPI. With the implementation of the suggested organizational solutions, Centers achieved relevant results, positively impacting on all the phases of the patient journey: decrease in waiting lists (-23%) and in the time length to transit the Center (-22%), increase in the percentage of new diagnoses (+20%), in the saturation of outpatient clinic capacity (+16%), and in the patient satisfaction (+4%). Centers involved in the "Early SpA Clinic" implemented several organizational actions based on an overall assessment of their activities and on solutions that required no additional resources. Overall, the Centers achieved the "Early SpA Clinic" objectives in terms of better management of resources, personnel, spaces, equipment, in relation to the volumes of patients.

Published
2022

41. Early Spondyloarthritis Clinic: Organizational Improvements in the Patient Journey

Author

D'Angelo, Salvatore, primary, Afeltra, Antonella, additional, Atzeni, Fabiola, additional, Baldissera, Elena, additional, Caminiti, Maurizio, additional, Ciccia, Francesco, additional, D'Agostino, Maria Antonietta, additional, Dagna, Lorenzo, additional, Erre, Gian Luca, additional, Franceschini, Franco, additional, Fusaro, Enrico, additional, Giacomelli, Roberto, additional, Gremese, Elisa, additional, Guggino, Giuliana, additional, Lomater, Claudia, additional, Lubrano, Ennio, additional, Padula, Angela Anna, additional, Pagano Mariano, Giuseppa, additional, Russo, Romualdo, additional, Sarzi Puttini, Piercarlo, additional, Scarpa, Raffaele, additional, Selmi, Carlo, additional, Tirri, Enrico, additional, Ferri, Stefano, additional, and Iannone, Florenzo, additional

Published
2022
Full Text
View/download PDF

42. Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey

Author

Thakare, Darpan, Naveen, R., Pauling, John, Ahmed, Sakir, Wincup, Chris, Del Papa, Nicolletta, Sambataro, Gianluca, Atzeni, Fabiola, Govoni, Marcello, Parisi, Simone, Bocci, Elena Bartoloni, Sebastiani, Gian Domenico, Fusaro, Enrico, Sebastiani, Marco, Quartuccio, Luca, Franceschini, Franco, Sainaghi, Pier Paolo, Orsolini, Giovanni, Angelis, Rossella, Danielli, Maria Giovanna, Venerito, Vincenzo, Sen, Parikshit, Kim, Minchul, Gracia-Ramos, Abraham Edgar, Akira Yoshida, Lilleker, James B., Agarwal, Vishwesh, Kardes, Sinan, Day, Jessica, Milchert, Marcin, Joshi, Mrudula, Gheita, Tamer A., Salim, Babur, Parodis, Ioannis, Selva O Callaghan, Albert, Nikiphorou, Elena, Chatterjee, Tulika, Tan, Ai Lyn, Nune, Arvind, Cavagna, Lorenzo, Shinjo, Samuel, Ziade, Nelly, Knitza, Johannes, Chinoy, Hector, Distler, Oliver, Kuwana, Masataka, Aggarwal, Rohit, Gupta, Latika, Agarwal, Vikas, and Makol, Ashima

Published
2022

43. Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey

Author

Ahmed, Sakir, Naveen, R., Pauling, John, Thakare, Darpan, Wincup, Chris, Del Papa, Nicoletta, Sambataro, Gianluca, Atzeni, Fabiola, Parisi, Simone, Govoni, Marcello, Bocci, Elena Bartoloni, Sebastiani, Gian Domenico, Fusaro, Enrico, Sebastiani, Marco, Quartuccio, Luca, Franceschini, Franco, Sainaghi, Pier Paolo, Orsolini, Giovanni, Angelis, Rossella, Danielli, Maria Giovanna, Venerito, Vincenzo, Sen, Parikshit, Kim, Minchul, Gracia-Ramos, Abraham Edgar, Akira Yoshida, Lilleker, James B., Agarwal, Vishwesh, Kardes, Sinan, Day, Jessica, Joshi, Mrudula, Milchert, Marcin, Gheita, Tamer A., Salim, Babur, Parodis, Ioannis, Selva O Callaghan, Albert, Nikiphorou, Elena, Chatterjee, Tulika, Tan, Ai Lyn, Nune, Arvind, Cavagna, Lorenzo, Shinjo, Samuel, Ziade, Nelly, Knitza, Johannes, Chinoy, Hector, Distler, Oliver, Kuwana, Masataka, Aggarwal, Rohit, Gupta, Latika, Agarwal, Vikas, and Makol, Ashima

Published
2022

44. Additional file 1 of Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study

Author

Colombo, Delia, Frassi, Micol, Pagano Mariano, Giusy, Fusaro, Enrico, Lomater, Claudia, Del Medico, Patrizia, Iannone, Florenzo, Foti, Rosario, Limonta, Massimiliano, Marchesoni, Antonio, Raffeiner, Bernd, Viapiana, Ombretta, Grassi, Walter, Grembiale, Rosa Daniela, Guggino, Giuliana, Mazzone, Antonino, Tirri, Enrico, Perricone, Roberto, Sarzi Puttini, Pier Carlo, De Vita, Salvatore, Conti, Fabrizio, Ori, Alessandra, Simoni, Lucia, Fiocchi, Martina, Orsenigo, Roberto, and Zagni, Emanuela

Abstract

Additional file 1: Socio-demographic and clinical characteristics at enrollment/start of biologic treatment under analysis (in Secukinumab and TNFis patients). In this file main socio-demographic and clinical characteristics at enrollment/start of biologic treatment under analysis are described in the groups of patients treated with Secukinumab and with TNFis.

Published
2022
Full Text
View/download PDF

45. Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort

Author

Gremese, Elisa, primary, Ciccia, Francesco, additional, Selmi, Carlo, additional, Cuomo, Giovanna, additional, Foti, Rosario, additional, Matucci-Cerinic, Marco, additional, Conti, Fabrizio, additional, Fusaro, Enrico, additional, Guggino, Giuliana, additional, Iannone, Florenzo, additional, Delle Sedie, Andrea, additional, Perricone, Roberto, additional, Idolazzi, Luca, additional, Moscato, Paolo, additional, Theander, Elke, additional, Noël, Wim, additional, Bergmans, Paul, additional, Marelli, Silvia, additional, Gossec, Laure, additional, and Smolen, Josef S., additional

Published
2022
Full Text
View/download PDF

46. Effectiveness of SB4 transition from originator etanercept in rheumatoid arthritis and axial spondyloarthritis: A subgroup analysis from the BENEFIT study

Author

Luciano, Nicoletta, primary, Fusaro, Enrico, additional, Ditto, Maria Chiara, additional, Ianniello, Aurora, additional, Bellis, Emanuela, additional, Bruni, Cosimo, additional, Viapiana, Ombretta, additional, Gremese, Elisa, additional, Migliore, Alberto, additional, Romoli, Ester, additional, Conforti, Ludovica, additional, Govoni, Marcello, additional, Matucci-Cerinic, Marco, additional, and Selmi, Carlo, additional

Published
2022
Full Text
View/download PDF

47. Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis

Author

Becciolini, Andrea, primary, Parisi, Simone, additional, Caccavale, Rosalba, additional, Bravi, Elena, additional, Lumetti, Federica, additional, Andracco, Romina, additional, Volpe, Alessandro, additional, Gardelli, Lucia, additional, Girelli, Francesco, additional, Di Donato, Eleonora, additional, Santilli, Daniele, additional, Lucchini, Gianluca, additional, Ditto, Maria Chiara, additional, Platè, Ilaria, additional, Arrigoni, Eugenio, additional, Mozzani, Flavio, additional, Riva, Michele, additional, Marchetta, Antonio, additional, Fusaro, Enrico, additional, Sandri, Gilda, additional, Salvarani, Carlo, additional, Paroli, Marino, additional, and Ariani, Alarico, additional

Published
2022
Full Text
View/download PDF

48. Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study

Author

Parisi, Simone, primary, Becciolini, Andrea, additional, Ditto, Maria Chiara, additional, Rozza, Davide, additional, Zanetti, Anna, additional, Laganà, Angela, additional, Peroni, Clara Lisa, additional, Centanaro Di Vittorio, Chiara, additional, Degiovanni, Rosanna, additional, Realmuto, Cristina, additional, Scirè, Carlo Alberto, additional, Priora, Marta, additional, Di Donato, Eleonora, additional, Santilli, Daniele, additional, Mozzani, Flavio, additional, Lucchini, Gianluca, additional, Ariani, Alarico, additional, Gardelli, Lucia, additional, Girelli, Francesco, additional, Arrigoni, Eugenio, additional, Platè, Ilaria, additional, Bravi, Elena, additional, Paroli, Marino, additional, Caccavale, Rosalba, additional, Salvarani, Carlo, additional, Sandri, Gilda, additional, Lumetti, Federica, additional, Volpe, Alessandro, additional, Marchetta, Antonio, additional, and Fusaro, Enrico, additional

Published
2022
Full Text
View/download PDF

49. New Onset of Giant Cell Arteritis following ChAdOx1-S (Vaxevria ®) Vaccine Administration.

Author

Lo Sardo, Luca, Parisi, Simone, Ditto, Maria Chiara, De Giovanni, Rosanna, Maletta, Francesca, Grimaldi, Serena, Brussino, Luisa, and Fusaro, Enrico

Subjects
GIANT cell arteritis, COVID-19 vaccines, VACCINATION complications, TEMPORAL arteries, C-reactive protein, FATIGUE (Physiology)
Abstract

We report a 78-year-old man presenting with persistent headaches in vertex and temporo-parietal area; fatigue, worsening after walking; jaw claudication; scotomas; pharyngodynia; and dry cough after the second dose of the SARS-CoV-2 vaccine (ChAdOx1-S) administration. Laboratory findings showed an elevated C-reactive protein level and FDG-CT PET showed evidence of active large vessel vasculitis with diffuse abnormal artery uptake. Under suspicion of vasculitis, a temporal arteries biopsy was performed; the histopathologic findings demonstrated the transmural inflammatory infiltrate with giant cells, compatible with giant cell arteritis. Although the overall incidence of vaccine-triggered autoimmunity is low, rheumatologists worldwide should be aware of autoimmune diseases as a new potential adverse event of vaccines. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study

Author

Ferri, Clodoveo, Giuggioli, Dilia, Raimondo, Vincenzo, Dagna, Lorenzo, Riccieri, Valeria, Zanatta, Elisabetta, Guiducci, Serena, Tavoni, Antonio, Foti, Rosario, Cuomo, Giovanna, De Angelis, Rossella, Cozzi, Franco, Murdaca, Giuseppe, Cavazzana, Ilaria, Romeo, Nicoletta, Codullo, Veronica, Ingegnoli, Francesca, Pellegrini, Roberta, Varcasia, Giuseppe, Della Rossa, Alessandra, De Santis, Maria, Abignano, Giuseppina, Colaci, Michele, Caminiti, Maurizio, L'Andolina, Massimo, Lubrano, Ennio, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Bellando-Randone, Silvia, Visalli, Elisa, Bilia, Silvia, Giannini, Daiana, Masini, Francesco, Pellegrino, Greta, Pigatto, Erika, Generali, Elena, Dall'Ara, Francesca, Pagano Mariano, Giuseppa, Barsotti, Simone, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Scorpiniti, Daniela, Ferrari, Tommaso, Caminiti, Rodolfo, Campochiaro, Corrado, Cecchetti, Riccardo, Gigliotti, Pietro, Olivo, Domenico, Ursini, Francesco, Brusi, Veronica, Meliconi, Riccardo, Scarpa, Raffaele, Fusaro, Enrico, Zignego, Anna Linda, D'Angelo, Salvatore, Iannone, Florenzo, Matucci-Cerinic, Marco, Doria, Andrea, Miccoli, Mario, Paparo, Sabrina Rosaria, Ragusa, Francesca, Elia, Giusy, Ferrari, Silvia Martina, Fallahi, Poupak, Antonelli, Alessandro, Rossa, Alessandra Della, and Mariano, Giuseppa Pagano

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results